

From: [Giordano, Erica](#)
To: [Patel, Manisha \(manisha.patel@novartis.com\)](#)
Cc: ["Riggins, Cindy"; narin.ahmed@novartis.com](#)
Subject: BL 125646 Clinical Information Request
Date: Friday, June 09, 2017 9:00:25 AM
Attachments: [image001.png](#)

Good morning,

Please see the information request below and provide a response by COB today, June 9, 2017.

Please confirm that Table 1-3.1 in your updated Safety Report only represents Bridging Chemotherapy from the time of pheresis to prior to lymphodepletion. If this is not the case please provide a table that details the exposure of the B2202 Safety Set (n=68) to chemotherapy as well as the specific details on the agents and exposure.

Please confirm receipt of this request.

Thank you,

Erica Giordano

Regulatory Project Manager

Center for Biologics Evaluation and Research

Office of Tissues and Advanced Therapies

U.S. Food and Drug Administration

Tel: 240-402-8298

Erica.Giordano@fda.hhs.gov



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."